| I-01 Thomas Dumortier Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development Wednesday 10:20-11:40 |
| I-02 Mike Dunlavey A new language for complex ODE models Wednesday 10:20-11:40 |
| I-03 Sulav Duwal Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1 Wednesday 10:20-11:40 |
| I-04 Lisa Ehmann Pharmacokinetics of meropenem in critically ill patients with varying renal function Wednesday 10:20-11:40 |
| I-05 Miro Eigenmann PBPK modeling approach to study the impact of lymph flow on the biodistribution of therapeutic antibodies Wednesday 10:20-11:40 |
| I-06 Raouf EL Cheikh A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer Wednesday 10:20-11:40 |
| I-07 Yumi Yamamoto Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data Wednesday 10:20-11:40 |
| I-08 Gregory Ferl Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics Wednesday 10:20-11:40 |
| I-09 Eric Fernandez Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical Wednesday 10:20-11:40 |
| I-10 Natalie Filmann Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation Wednesday 10:20-11:40 |
| I-11 Linda Franken Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients Wednesday 10:20-11:40 |
| I-12 Jonathan French A case study in comparing cognitive development across populations Wednesday 10:20-11:40 |
| I-13 Nicolas Frey Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab Wednesday 10:20-11:40 |
| I-14 Aline Fuchs Simulations to simplify gentamicin dosing regimens for neonates and young infants when referral is not possible in developing countries Wednesday 10:20-11:40 |
| I-15 Saskia Fuhrmann Generic PBPK model to predict preclinical and clinical PK of antibodies Wednesday 10:20-11:40 |
| I-16 María García-Cremades A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer Wednesday 10:20-11:40 |
| I-17 Peter Gennemark Unravelling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor-antidote) using mouse data Wednesday 10:20-11:40 |
| I-18 Eva Germovsek Pharmacokinetic-pharmacodynamic (PKPD) modelling of meropenem in plasma and cerebrospinal fluid (CSF) in infants with late-onset sepsis and/or bacterial meningitis Wednesday 10:20-11:40 |
| I-19 Andy Gewitz PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration Wednesday 10:20-11:40 |
| I-20 Ekaterina Gibiansky Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) Wednesday 10:20-11:40 |
| I-21 Leonid Gibiansky vc-MMAE antibody-drug conjugates: a unified model describes pharmacokinetics of eight different compounds Wednesday 10:20-11:40 |
| I-22 Anais Glatard Influence of UGT2B7 polymorphism on varenicline clearance in a cohort of smokers from the general population Wednesday 10:20-11:40 |
| I-23 Britta Goebel Modeling & Simulation of Long-Term Body Weight Loss during Obesity Pharmacotherapy Wednesday 10:20-11:40 |
| I-24 Bojana Golubovic Population modelling of sirolimus data available from routine therapeutic drug monitoring Wednesday 10:20-11:40 |
| I-25 Ignacio Gonzalez-Garcia Assessment of in vitro dissolution specifications based on an IVIVC and in vivo bioequivalence criteria Wednesday 10:20-11:40 |
| I-26 Verena Gotta Characterizing age-dependency of cytokine levels in healthy children Wednesday 10:20-11:40 |
| I-27 Gopichand Gottipati Item Response Modeling to Leverage Data from Historical Parkinson’s Disease Trials while Integrating Data from a Newer Version of the Clinical Endpoint Wednesday 10:20-11:40 |
| I-28 Sebastiaan Goulooze Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours. Wednesday 10:20-11:40 |
| I-29 Sylvain Goutelle A nonparametric, multiple-model approach to optimize initial dosing and attainment of a target exposure interval: application to busulfan in pediatrics Wednesday 10:20-11:40 |
| I-30 Joachim Grevel Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC) Wednesday 10:20-11:40 |
| I-31 Monia Guidi Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients Wednesday 10:20-11:40 |
| I-32 Elham Haem Adjusted adaptive lasso for covariate model building in nonlinear mixed effects models Wednesday 10:20-11:40 |
| I-34 Janelle Hajjar Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test Wednesday 10:20-11:40 |
| I-35 Nayoung Han Dose estimation based on population pharmacokinetic/pharmacogenetic modeling for enteric-coated mycophenolate sodium in kidney transplant recipients Wednesday 10:20-11:40 |
| I-36 Nina Hanke Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin Wednesday 10:20-11:40 |
| I-37 Fangran Hao Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft Wednesday 10:20-11:40 |
| I-38 Paul Healy Model-based dose selection of tocilizumab for the prevention of reperfusion injury. Wednesday 10:20-11:40 |
| I-39 Michael Heathman A Categorical Time Course PKPD Model Describing the Effect of Ixekizumab on Improvement from Baseline in Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis Wednesday 10:20-11:40 |
| I-40 Andrea Henrich PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model Wednesday 10:20-11:40 |
| I-41 Christoph Hethey Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays Wednesday 10:20-11:40 |
| I-42 Jennifer Hibma Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients Wednesday 10:20-11:40 |
| I-43 Eef Hoeben Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir Wednesday 10:20-11:40 |
| I-44 Christian Hollensen Estimation of random variance in NONMEM using different approaches Wednesday 10:20-11:40 |
| I-45 Xiao Hu Population pharmacokinetic analysis of fampridine in Japanese patients with multiple sclerosis in a Phase 3 study Wednesday 10:20-11:40 |
| I-47 Stephen Duffull The influence of parameterisation on local identifiability Wednesday 10:20-11:40 |
| I-48 Manuel Ibarra Pharmacokinetic characterization of naphtalophos in lambs by modelling blood acetylcholinesterase activity, a K-PD model Wednesday 10:20-11:40 |
| I-49 Moustafa M. A. Ibrahim Importance of hot glucose for the integrated glucose-insulin minimal model Wednesday 10:20-11:40 |
| I-50 Diane-Charlotte Imbs Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer Wednesday 10:20-11:40 |
| I-51 Itziar Irurzun-Arana Attractor analysis of Boolean models for Systems Pharmacology Networks Wednesday 10:20-11:40 |
| I-52 Swati Jaiswal Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters Wednesday 10:20-11:40 |
| I-53 Masoud Jamei Time variation in the fractional contribution of an enzyme to elimination of a victim drug can explain differences in DDI susceptibility following single and multiple dosing Wednesday 10:20-11:40 |
| I-54 Félix Jaminion Use of a drug-drug interaction study with itraconazole to quantify the effects of an NME on QT interval duration Wednesday 10:20-11:40 |
| I-55 Carl Johansson Omeprazole dose recommendation in pediatric patients aged 1-11 months with erosive esophagitis Wednesday 10:20-11:40 |
| I-56 Jong Bong Lee Predicted versus experimental permeability data for incorporation into GastroPlus™ for modelling and simulations Wednesday 10:20-11:40 |
| I-57 Daniel Jonker Personalized dosing of a novel recombinant human FSH, follitropin delta, based on individual patient characteristics Wednesday 10:20-11:40 |
| I-58 Marija Jovanovic Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients Wednesday 10:20-11:40 |
| I-59 Matts Kågedal Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study. Wednesday 10:20-11:40 |
| I-60 Tatiana Karelina Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model Wednesday 10:20-11:40 |
| I-61 Anhye Kim Population Pharmacokinetic/Pharmacoynamic Models to evaluate the positive and delayed effect of escitalopram on QT prolongation Wednesday 10:20-11:40 |
| I-62 Anke Kip Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients Wednesday 10:20-11:40 |
| I-63 Lena Klopp-Schulze Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations Wednesday 10:20-11:40 |
| I-64 Katrine Knøsgaard A model-based approach for joint analysis of pain intensity and opioid consumption in postoperative pain Wednesday 10:20-11:40 |
| I-65 Gilbert Koch Facilitate treatment adjustment after accidental overdosing: pharmacometric modelling to support clinical practice Wednesday 10:20-11:40 |
| I-66 Anders Kristoffersson Design and Interim Evaluation of a Sparse Sampling Schedule for Estimation of Individual Colistin Pharmacokinetics Wednesday 10:20-11:40 |
| I-67 Anne Kuemmel PECAN, a Shiny application for calculating confidence and prediction intervals for pharmacokinetic and pharmacodynamic models Wednesday 10:20-11:40 |
| I-68 Manish Kumar Elucidating metabolic variations in gut microbiota during health and malnutrition based on genome scale metabolic modeling approach Wednesday 10:20-11:40 |
| I-69 Max Lagraauw A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015 Wednesday 10:20-11:40 |
| I-70 Laure Lalande Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid Wednesday 10:20-11:40 |
| I-71 Silvia Maria Lavezzi Structural and practical identifiability of some mPBPK-TMDD models Wednesday 10:20-11:40 |
| I-72 Jean Lavigne Modeling and simulation of smear count after administration of Eurartesim® (piperaquine (PQ) tetraphosphate/dihydroartemisinin (DHA)) in infected patients with Plasmodium falciparum malaria Wednesday 10:20-11:40 |
| I-73 Mary Lavy Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS) Wednesday 10:20-11:40 |
| I-74 Robert Leary An Improved Framework for Shrinkage Computations in NLME Population Models Wednesday 10:20-11:40 |
